By Carrie Capili, Communications Specialist, Editor
The National Comprehensive Cancer Network® (NCCN®) has launched NCCNChina.org, a valuable online resource for clinical professionals and other health care decision-makers in China. NCCNChina.org currently features the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – China Editions. Based on the NCCN Guidelines™, the China Editions comprise the extensive expertise of more than 100 Chinese cancer specialists in collaboration with NCCN panel experts. The China Editions contain recommendations revised specifically to account for genetic, pharmacological, and regulatory considerations of the Chinese population.
NCCNChina.org is committed to providing Chinese oncologists with the latest information in cancer management and aims to increase familiarity and understanding of the NCCN Guidelines among Asian oncologists in order to improve the effectiveness of treatment for a broader population of patients with cancer. Through NCCNChina.org and the collaborative efforts of NCCN and Chinese thought leaders, NCCN looks forward to serving as an important resource of clinical data for the oncology community in China.
The NCCN Guidelines are the recognized standard for clinical policy in oncology in the United States. Expert clinicians across Asia recognize and apply the NCCN Guidelines in practice and have collaborated with NCCN on the translation, adaptation, and implementation of national versions of the NCCN Guidelines. NCCN and cancer-care thought leaders in China have had a long-standing collaboration in the development of the NCCN Guidelines – China Editions - the most authoritative reference for oncology practice in China. Indeed, of the 1.1 million unique visitors to the NCCN website (www.nccn.org) every year, almost 300,000 are from Asian countries. Forty-six thousand unique visitors are from China.
NCCN regularly collaborates with international organizations around the world to create and distribute translations of the NCCN Guidelines, which may include modifications representative of metabolic differences in populations, technological considerations, and regulatory status of agents used in cancer management, such as availabilities of drugs, biologics, devices, and procedures.